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Effect of Ghrelin Injection on Blood and Body Composition in Rats
Abstract
Ghrelin has been reported to cause hyperglycemia in humans and adiposity in rodents. The objective of trial
one was to test the effects of ghrelin on blood and body composition in rats. The objective of trial two was to
evaluate the effect of two doses of ghrelin on blood and body composition. Trial One: Adult male Sprague
Dawley rats were administered 1 μg/rat ghrelin in 0.15 M NaCl or vehicle (0.15 M NaCl) every morning for
30 days. The terminal blood sample was analyzed for glucose, urea nitrogen, and nonesterified fatty acids
concentrations. The carcasses were analyzed for total lipid and nitrogen content. Blood urea nitrogen,
nonesterified fatty acids, carcass total lipid, and carcass total nitrogen concentrations were similar for the
control and ghrelin groups. However, blood glucose concentration tended to be higher in the ghrelin group
than in the control. Ghrelin administered at 2.4 μg/kg did not cause adiposity in rats but did tend to cause
hyperglycemia. Trial Two: Adult male Sprague Dawley rats were administered 1 μg/rat ghrelin, 20 μg/rat
ghrelin, or vehicle every morning for 30 days. The terminal blood sample was analyzed for glucose and
cholesterol concentrations. The carcasses were analyzed for total lipid and nitrogen content. Carcass total
nitrogen concentrations were similar for the control and ghrelin groups. Carcass percent lipid was higher in
the 1 μg/rat ghrelin group (P = 0.04). Feed intake among all three groups was the same. Blood glucose
concentration, however, tended to be higher in the ghrelin groups than in the control. Blood cholesterol
concentration was lower in the ghrelin treated animals. In the second trial, ghrelin injection of 1 μg/rat did
cause an increase in adiposity whereas 20 μg/rat did not cause an increase in adiposity. Both ghrelin
treatments tended to cause hyperglycemia in rats. In summary, ghrelin increased blood glucose concentration
without changing body composition.
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Summary 
Ghrelin has been reported to cause hyperglycemia in 
humans and adiposity in rodents.  The objective of trial 
one was to test the effects of ghrelin on blood and body 
composition in rats.  The objective of trial two was to 
evaluate the effect of two doses of ghrelin on blood and 
body composition.  Trial One: Adult male Sprague 
Dawley rats were administered 1 µg/rat ghrelin in 0.15 
M NaCl or vehicle (0.15 M NaCl) every morning for 30 
days.  The terminal blood sample was analyzed for 
glucose, urea nitrogen, and nonesterified fatty acids 
concentrations.  The carcasses were analyzed for total 
lipid and nitrogen content.  Blood urea nitrogen, 
nonesterified fatty acids, carcass total lipid, and carcass 
total nitrogen concentrations were similar for the control 
and ghrelin groups.   However, blood glucose 
concentration tended to be higher in the ghrelin group 
than in the control.  Ghrelin administered at 2.4 µg/kg 
did not cause adiposity in rats but did tend to cause 
hyperglycemia.  Trial Two: Adult male Sprague Dawley 
rats were administered 1 µg/rat ghrelin, 20 µg/rat 
ghrelin, or vehicle every morning for 30 days.  The 
terminal blood sample was analyzed for glucose and 
cholesterol concentrations.  The carcasses were analyzed 
for total lipid and nitrogen content.  Carcass total 
nitrogen concentrations were similar for the control and 
ghrelin groups.  Carcass percent lipid was higher in the 
1 µg/rat ghrelin group (P = 0.04).  Feed intake among all 
three groups was the same.    Blood glucose 
concentration, however, tended to be higher in the 
ghrelin groups than in the control.  Blood cholesterol 
concentration was lower in the ghrelin treated animals.  
In the second trial, ghrelin injection of 1 µg/rat did cause 
an increase in adiposity whereas 20 µg/rat did not cause 
an increase in adiposity.  Both ghrelin treatments tended 
to cause hyperglycemia in rats.  In summary, ghrelin 
increased blood glucose concentration without changing 
body composition.   
 
Introduction 
 Body composition is important to beef cattle producers.  
The hormone ghrelin is involved in regulating feed intake 
and body composition.  Ghrelin is a newly discovered 
hormone that acts upon the growth hormone secretagogue 
receptor (GSH-R).  The GSH-R was discovered in the 
1970s.  There are many synthetic compounds that act upon 
this receptor to change the animal’s body composition. 
Since the discovery of the GSH-R, the search for an 
endogenous ligand has been conducted.  In 1999, ghrelin 
was discovered (Kojima et al. 1999) to be an endogenous 
ligand of this receptor. 
 Ghrelin is composed of 28 acids with an octanoic acid 
attached at Ser 3.  The octanoyl moiety is required for 
activity and gives ghrelin its specificity for the growth 
hormone secretagogue receptor (GHSR).   Ghrelin is 
synthesized primarily in the fundus region of the stomach, 
although other tissues produce ghrelin in small amounts. 
 Since the discovery and isolation of ghrelin, many 
studies have been performed to determine the biochemical 
and physiological functions of ghrelin in the body.  Ghrelin 
stimulates growth hormone release independent of the 
growth hormone releasing hormone (Kojima et al. 1999). 
Additionally, leptin activity is controlled by ghrelin.  
Ghrelin is an antagonist of leptin by acting upon the 
neuropeptide Y/Y1 receptor pathway (Shintani et al. 2001).  
Leptin causes satiety, whereas ghrelin stimulates nutrient 
intake (Nakazato et al. 2001).  Leptin and ghrelin regulate 
the action of each other.  Ghrelin has been reported to 
increase accretion of adipose tissue in rats.  After ghrelin 
injection, hyperglycemia and decrease in insulin 
concentration was observed in humans.     
The overall objective of our study is to investigate the effect 
of ghrelin on hormones involved in the metabolic pathways 
related to physiological changes.  The objective of the first 
trial was to determine the effect ghrelin on blood and body 
composition.  The main focus of second study was to 
evaluate the effect of two doses of ghrelin on blood and 
body composition.  We hypothesize that ghrelin will cause 
hyperglycemia, insulinemia, and adiposity in the 20 µg/rat 
ghrelin group and slight hyperglycemia and insulinemia in 
the 1 µg/rat ghrelin group with no adiposity, with no change 
in the control group. 
   
Materials and Methods 
Trial One: Effect of ghrelin on blood and body composition. 
 Ten adult male Sprague Dawley rats (age 3 months) 
were assigned randomly to control (0.15M sodium chloride) 
or ghrelin (1 µg/rat) treatments.  Treatments were 
administered daily by subcutaneous injection.    Feed intake 
was measured daily for 2 weeks.  For the remainder of the 
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trial, rats were fed the average daily intake plus 10%.  Blood 
was collected from the saphenous vein on days 1, 7, 14, 21, 
and 28.  On each of those days, blood was collected before 
injection, and at 5, 10, 15, and 20 minutes after injection.  
Serum samples were analyzed for glucose (Sigma) and 
insulin (Linco Research) concentrations.  Rats were 
euthanized using CO2 anesthesia.  Terminal plasma samples 
were collected by using cardiac puncture.  Carcass (body 
without head, skin, tail, feet, entrails, gastrocnemius muscle, 
and femurs), liver, femurs, and gastrocnemius muscle were 
harvested.  Plasma samples were analyzed for glucose 
(Sigma), nonesterified fatty acids (NEFA, Wako 
Chemicals), and blood urea nitrogen (BUN, Sigma) 
concentrations.  Gastrocnemius muscle was weighed.  
Carcass protein was determined by micro Kjeldahl assay.  
Carcass and liver lipids were measured using modified 
Folch wet tissue lipid extraction.  Triacylglycerol content of 
liver was quantified colorimetrically (Pointe Scientific).  
Bone density was measured by using Archimedes‘ principle. 
 
Trial Two: Effect of two doses of ghrelin on blood and body 
composition.    
 Sixteen adult male Sprague Dawley rats (age 3 months) 
were assigned randomly to one of three treatments: control 
(0.15M sodium chloride), 1 µg/rat ghrelin, or 20 µg/rat 
ghrelin.  Treatments were administered daily by 
subcutaneous injection.  Rats were fed standard rat chow ad 
libitum.  Blood was collected from the saphenous vein on 
days 1 and 22 of the trial.  On each of those days, blood was 
collected before injection, and at 5, 10, 15, and 20 minutes 
after injection.  Serum samples were analyzed for glucose 
(Sigma) and insulin (Linco Research) concentrations.  Rats 
were euthanized using CO2 anesthesia.  Terminal plasma 
sample was collected using cardiac puncture.  Carcass (body 
without head, skin, tail, feet, entrails, gastrocnemius muscle, 
and femurs), femurs, and gastrocnemius muscle were 
harvested and stored at -20°C.  Liver and adipose tissue 
were collected, frozen in liquid nitrogen and stored at -80°C 
for future analysis.  Plasma samples were analyzed for 
glucose and cholesterol concentrations (Sigma).  Carcass 
protein was determined by micro Kjeldahl assay.  Carcass 
and liver lipids were measured by using modified Folch wet 
tissue lipid extraction.   
 
Results and Discussion 
Trial One 
 Femur density tended to be higher in the ghrelin group 
(3.68 g/cm3 ± 0.17) than in control group (3.3 g/cm3 ± 0.17, 
P = 0.17).  Because growth hormone reverses loss of bone 
marrow (Tseng, 1998), the gain in bone density and weight 
could be effects of increased growth hormone release by 
ghrelin.
 
 
Table One: Effect of ghrelin injection on blood metabolites. 
 
 
 
 
 
 
 
 
Metabolite                         Control                         Ghrelin                        P-value 
Glucose (mg/dl)                149.72 + 4.43                172.32 + 14.15          0.190 
NEFA (µeq/l)                    214.58 + 12.7                216.03 + 27.4            0.962 
Urea Nitrogen (mg/dl)       9.69 + 0.94                    9.71 + 0.62                0.988 
A = mean + SEM 
Significant at P < 0.1 
 
Table Two.  Effect of ghrelin injection on carcass measurements. 
Carcass Measurement                   Control                         Ghrelin                        P-value 
Total Lipid (% wet weight)            7.70 + 0.55A                      6.94 + 0.34                  0.917 
Total Protein (% dry weight)         67.1 + 0.96                  67.93 + 1.6                  0.698 
A = mean + SEM 
Significant at P < 0.1 
 
 
Table Three.  Liver Composition.  
                                                      Control                         Ghrelin                        P value 
Liver Lipid (% wet weight)           4.25 + 0.24A                      3.80 + 0.19                  0.176 
Liver Triacylglycerols (mg/dl)     30.88 + 1.75               26.59 + 1.56                 0.110 
A = mean + SEM 
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Figure One.  Effect of ghrelin injection on insulin concentration.  
Insulin Concentration vs. Time after Injection
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Figure Two.  Effect of ghrelin injection on glucose concentration.  
Glucose Concentration vs. Time after Injection
0
50
100
150
200
250
300
350
0 5 10 15 20 25
Time (min)
G
lu
co
se
 C
on
ce
nt
ra
tio
n 
(m
g/
dl
)
Ghrelin
Control
Mean ± SEM 
Significant p<0.1 
Treatment effect p = 0.08 
 
   
Figure 3.  Total feed intake of treatment groups during injection period. 
Feed Intake
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Table Four.  Effect of two doses of ghrelin on carcass measurements. 
Treatment                              Lipid (% of carcass)              Nitrogen (% of carcass)        
Control                                   4.68 ± 0.34A a                             12.6 ± 0.55                                           
1 µg/d Ghrelin                        5.84 ± 0.37b                               11.5 ± 0.6 
20 µg/d Ghrelin                     5.09 ± 0.37 ab                                       12.2 ± 0.6     
A = mean + SEM 
different small letters indicate significant differences between groups at P ≤ 0.1 
 
Table Five.  Effect of two doses of ghrelin on blood metabolites.  
Treatment                                    Glucose (mg/dl)                      Cholesterol (mg/dl) 
Control                                        135.5 ± 6.5A                            113.1 ± 3.5a 
1 µg/d Ghrelin                             149.2 ± 7.2                              101.7 ± 3.9 abc 
20 µg/d Ghrelin                           150.6 ± 7.2                              111.8 ± 3.9 bc 
A = mean + SEM 
different small letters indicate significant differences between groups at P ≤ 0.1 
      In previous studies, ghrelin has caused adiposity in rats 
(Tschop, 2000).  In trial one, however, there was no 
significant difference in carcass lipid or protein.  The 
gastrocnemius muscle weights of control and ghrelin 
treatments were similar (P = 0.738).    
 Liver lipids and liver triacylglycerols tended to be 
lower in the ghrelin group.  Ghrelin stimulates growth 
hormone release. Growth hormone has been reported to 
decrease glucose production and increase lipid oxidation in 
the liver (Piatti, 1999).  The increase in lipid oxidation could 
explain the decrease in liver lipids and triacylglycerols.   
 Blood urea nitrogen and NEFA were similar in the 
ghrelin and control groups.   Blood cholesterol was higher 
in the ghrelin treatment. Terminal blood glucose tended to 
be higher in the ghrelin group than in the control, 
demonstrating a mild hypoglycemic effect of ghrelin. 
The results indicate that ghrelin caused a decrease in 
insulin concentration and an increase in glucose 
concentration (Figures One and Two).  Ghrelin injection 
caused hyperglycemia in rats over time while causing a 
decrease in insulin concentration.  This result is consistent 
with the known physiological effects of ghrelin (Broglio, 
2001).   
 
Trial Two 
 In the second trial, the group administered the 1 µg/d 
ghrelin group had a significantly higher percent carcass lipid 
than the control (P =0.03).  The 20 µg/d ghrelin group was 
not significantly different from the control (P = 0.43).  
Ghrelin has been reported to cause adiposity in rats.  The 
increase in lipid percent in the 1 µg/d ghrelin group is 
consistent with those findings.  However, the 20 µg/d 
ghrelin group did not have a higher percent lipid, which was 
not expected.  The increase in adiposity in the 1 µg/d ghrelin 
group and not in the 20 µg/d ghrelin group is not does not 
have a clear explanation.   The treatment groups did not 
significantly differ in carcass percent nitrogen (P > 0.21).   
       To determine if the rats with a higher percent lipid 
ingested more feed, the feed intake of the three treatments 
groups were measured.  Because the three treatment groups 
did not significantly differ in feed intake, the effect of 
ghrelin on adiposity is not a result of greater dietary energy.
 Blood glucose tended to be higher in the in the ghrelin 
groups versus the control (P = 0.18).  The 1 µg/d ghrelin 
group was higher than the control (P = 0.18) but lower than 
the 20 µg/d ghrelin group (P =0.14).  The daily injection of 
ghrelin seems to have elevated the blood glucose in a dose-
dependent manner.  Serum cholesterol was lower in the rats 
given 1 µg/d ghrelin (P = 0.04).  Rats in the 20 µg/d ghrelin 
and the control groups were similar in serum cholesterol 
concentration (P = 0.82). 
 
Implications 
In trial one, ghrelin did not have an effect on 
adiposity. Bone density was greater in the ghrelin 
treated rats.  Hyperglycemia and a decrease in 
insulin concentration were observed in ghrelin 
treated rats.  In trial two, lean mass was not 
effected by ghrelin, but the rats given 1 µg/d 
ghrelin had an increase in adiposity.  Blood 
cholesterol concentration was decreased by the 1 
µg/d ghrelin treatment, but not the 20 µg/d ghrelin 
treatment.  Both doses of ghrelin caused 
hyperglycemia; the greater dose caused the greater 
increase.  The second study demonstrated an 
increase in adiposity in rats treated with 1 µg/d 
ghrelin. Both ghrelin treatments tended to cause 
hyperglycemia in rats.  In summary, ghrelin 
increased blood glucose concentration without 
changing body composition.   
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